150 related articles for article (PubMed ID: 34555730)
1. Two cases of non-small cell lung cancer patients with somatic or germline EGFR R776H mutation.
Guo T; Zhu L; Li W; Lin R; Ding Y; Kang Q; Shao L; Li C; Pan X
Lung Cancer; 2021 Nov; 161():94-97. PubMed ID: 34555730
[TBL] [Abstract][Full Text] [Related]
2. A Primary Lung and Breast Cancer Patient with Germline
Li D; Liu X; Cui S; Yang D; Zhu Y; Pan E; Yang P; Dai Z
Onco Targets Ther; 2023; 16():17-22. PubMed ID: 36698436
[TBL] [Abstract][Full Text] [Related]
3. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.
Kobayashi S; Canepa HM; Bailey AS; Nakayama S; Yamaguchi N; Goldstein MA; Huberman MS; Costa DB
J Thorac Oncol; 2013 Jan; 8(1):45-51. PubMed ID: 23242437
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib.
Longo V; Catino A; Montrone M; Pizzutilo P; Pesola F; Marech I; Capone I; Prelaj A; Galetta D
Thorac Cancer; 2021 Jul; 12(13):2031-2034. PubMed ID: 34008923
[TBL] [Abstract][Full Text] [Related]
5. Familial rare EGFR-mutant lung cancer syndrome: Review of literature and description of R776H family.
Gabriel L; McVeigh T; Macmahon S; Avila Z; Donovan L; Hunt I; Draper A; Minchom A; Popat S; Davidson M; Bhosle J; Milner Watts C; Hubank M; Yuan L; O'Brien M
Lung Cancer; 2024 May; 191():107543. PubMed ID: 38569279
[TBL] [Abstract][Full Text] [Related]
6. Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation.
Tanizaki J; Banno E; Togashi Y; Hayashi H; Sakai K; Takeda M; Kaneda H; Nishio K; Nakagawa K
Lung Cancer; 2016 Nov; 101():11-15. PubMed ID: 27794398
[TBL] [Abstract][Full Text] [Related]
7. First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea.
Kim MH; Choi CM; Lee SY; Park CK; Chang YS; Lee KY; Kim SJ; Yang SH; Ryu JS; Lee JE; Lee SY; Park CK; Lee SH; Jang SH; Yoon SH; Jang TW
Anticancer Res; 2022 Mar; 42(3):1615-1622. PubMed ID: 35220259
[TBL] [Abstract][Full Text] [Related]
8. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity of epidermal growth factor receptor with single or double uncommon mutations to afatinib confirmed by a visual assay.
Kimura S; Tanaka K; Harada T; Liu R; Shibahara D; Kawano Y; Nakanishi Y; Okamoto I
Cancer Sci; 2018 Nov; 109(11):3657-3661. PubMed ID: 30255614
[TBL] [Abstract][Full Text] [Related]
10. Case report: identification of EGFR R776H and FANCE R381H germline mutations in a patient with multiple pulmonary nodules.
Wu Z; Wang Y; Jin L; Wei J; Han L; Su J; Cao S; Liu S; Duan X; Zhao X
J Cancer Res Clin Oncol; 2023 Feb; 149(2):921-927. PubMed ID: 36163560
[TBL] [Abstract][Full Text] [Related]
11. Inter- and Intratumor Heterogeneity of EGFR Compound Mutations in Non-Small Cell Lung Cancers: Analysis of Five Cases.
Suda K; Sakai K; Obata K; Ohara S; Fujino T; Koga T; Hamada A; Soh J; Nishio K; Mitsudomi T
Clin Lung Cancer; 2021 Mar; 22(2):e141-e145. PubMed ID: 33051123
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study.
Kanazu M; Mori M; Kimura M; Nishino K; Shiroyama T; Nagatomo I; Ihara S; Komuta K; Suzuki H; Hirashima T; Kumagai T; Imamura F
Thorac Cancer; 2021 Jan; 12(1):90-96. PubMed ID: 33124128
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of afatinib in a patient with rare EGFR (G724S/R776H) mutations and amplification in lung adenocarcinoma: A case report.
He SY; Lin QF; Chen J; Yu GP; Zhang JL; Shen D
World J Clin Cases; 2021 Feb; 9(6):1329-1335. PubMed ID: 33644199
[TBL] [Abstract][Full Text] [Related]
14. Limited effect of afatinib in a non-small cell lung cancer patient harboring an epidermal growth factor receptor K860I missense mutation: A case report.
Tamura T; Kawakado K; Makimoto G; Nakanishi M; Kuyama S
Thorac Cancer; 2021 Jun; 12(11):1770-1774. PubMed ID: 33942527
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.
Russo A; Franchina T; Ricciardi G; Battaglia A; Picciotto M; Adamo V
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30901844
[TBL] [Abstract][Full Text] [Related]
16. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
17. Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations.
Sehgal K; Rangachari D; VanderLaan PA; Kobayashi SS; Costa DB
Oncologist; 2021 Apr; 26(4):281-287. PubMed ID: 32969527
[TBL] [Abstract][Full Text] [Related]
18. Durable complete response after afatinib and crizotinib in an advanced non-small cell lung cancer patient with EGFR L861Q mutation and acquired MET amplification: a case report.
Long Y; Zhang K; Li Y; Yu M; Zhu J; Huang M
Ann Palliat Med; 2020 Sep; 9(5):3609-3613. PubMed ID: 32648452
[TBL] [Abstract][Full Text] [Related]
19. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation.
Chantharasamee J; Poungvarin N; Danchaivijitr P; Techawatanawanna S
BMC Cancer; 2019 Jul; 19(1):701. PubMed ID: 31315599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
